News
Pain professionals news
Policy, clinical, and payment developments for pain management, rehabilitation, and integrative care — taken from the [NEWS] posts in the weekly feed and linked to the original reporting.
As of Monday morning, November 16, the DEA has still not published the temporary order that would put concentrated 7-hydroxymitragynine (7-OH) in Schedule I. The order could have appeared any day from Friday, November 13 onward, and it takes effect the day it is published, so today is the next day it could appear. The threshold is unchanged: products above 1 milligram of combined 7-OH and mitragynine pseudoindoxyl per gram or per milliliter, or with a mitragynine-to-7-OH ratio below 100 to 1. Natural kratom leaf is not the target, and Maryland already caps 7-OH at 2 percent of the alkaloid fraction under its own state law.
A secondary analysis of the phase 3 PANOVA-3 trial, published November 13 in JAMA Network Open, found that people with locally advanced pancreatic cancer who wore the Optune Pax device with chemotherapy went about three months longer before their pain worsened than those on chemotherapy alone: 10.1 months versus 7.4 months for general pain, and 14.7 versus 10.2 months for pancreatic cancer-specific pain. The trial enrolled 571 people. For clinics that see cancer-related pain, the result adds to the evidence that non-drug pain control can meaningfully delay worsening pain, though the device is used alongside chemotherapy, not instead of it.
Pain Jobs — a job board for pain management professionals.
The temporary federal rule that lets clinicians prescribe Schedule II through V controlled substances by telehealth without a prior in-person visit expires at the end of December 31, 2026. The DEA sent its permanent special-registration rule to the White House review office on August 25, and it was still under review as of November 9, with no fifth extension published as of November 11. If nothing is published before the deadline, the Ryan Haight Act's in-person evaluation requirement returns on January 1, 2027, so clinics that prescribe controlled substances by telehealth should have an in-person plan ready. A separate permanent rule for buprenorphine treatment by telehealth, in effect since December 31, 2025, is not affected.
Sources: Island Insurance Group, November 11, 2026, https://islandinsurancegroup.com/dea-telehealth-prescribing-deadline-2026/ ; DNP Consulting, November 9, 2026, https://www.dnpconsulting.org/post/dea-s-telemedicine-prescribing-proposal-and-how-prescribers-can-push-back
- Montana
The American Massage Therapy Association highlighted new research on Veterans Day showing massage therapy can reduce chronic pain and improve function for veterans, including a 2026 randomized trial in veterans with chronic neck pain. At the same time, the association is pressing Congress over a VA payment policy that could limit access to massage therapy. In Washington state, the dispute is already costing clinics: the state association reports 34 massage practices received combined recoupment demands of $337,139.10 from TriWest, the VA Community Care Network contractor, which is retroactively applying a Medicare multiple-procedure payment reduction to authorized services billed as far back as 2021.
Sources: American Massage Therapy Association, November 10, 2026, https://www.morningstar.com/news/pr-newswire/20261110cg94142/new-research-shows-massage-therapy-can-reduce-pain-and-improve-quality-of-life-for-veterans-and-military-service-members ; Washington State Massage Therapy Association, November 10, 2026, https://www.mywsmta.org/gr-news
- Physical therapy
Medicare's 2027 fee schedule cuts the conversion factor 2.31 percent, but physical and occupational therapy still come out ahead. The Alliance for Physical Therapy Quality and Innovation puts the net result at a 0.7 percent payment increase for PT and OT, because CMS is phasing out the indirect practice cost index that has discounted PT practice expenses for nearly two decades — halved in 2027 and gone in 2028 — and updating aquatic therapy equipment prices that had not changed in more than 20 years. The KX modifier threshold rises to $2,540 for 2027, and CMS dropped its proposal to pay for remote therapeutic monitoring only when done by practice-employed staff, though it did finalize limits to established patients and a separate initiating visit.
Sources: APTA, November 10, 2026, https://www.apta.org/article/2026/11/10/final-2027-physician-fee-schedule-has-mixed-payment-impact-for-physical-therapy ; Alliance for Physical Therapy Quality and Innovation, November 5, 2026, https://www.aptqi.com/news/aptqi-applauds-cms-for-finalizing-updates-to-physical-therapy-reimbursement-and-equipment-costs-in-2027-mpfs-final-rule/
The American College of Rheumatology's updated osteoarthritis guideline, reviewed at its annual meeting on November 10, strongly reinforces exercise as a treatment that can benefit virtually every patient with knee, hip, or hand osteoarthritis. Walking is a new recommendation that was not in the 2019 guideline. For patients with knee osteoarthritis and obesity, the guideline now conditionally recommends GLP-1 receptor agonists alongside diet and exercise to help reach a healthier weight.
As of November 10, the DEA has not published the temporary order that would place concentrated 7-hydroxymitragynine (7-OH) in Schedule I. The October 14 Federal Register notice says the order will publish on or after November 13, 2026, and it takes effect the day it is published, so tomorrow is the earliest it can appear. The threshold is unchanged: products above 1 milligram of combined 7-OH and mitragynine pseudoindoxyl per gram or per milliliter, or with a mitragynine-to-7-OH ratio below 100 to 1. Natural kratom leaf is not the target.
Pain Jobs — a job board for pain management professionals.
The experimental once-weekly injection retatrutide cut knee osteoarthritis pain by at least half in about two-thirds of trial participants with obesity, compared with 38 percent on placebo, in two phase 3 trials published November 8 in the New England Journal of Medicine. In the TRIUMPH-4 trial of 445 adults, pain scores fell 3.96 points on the 9 mg dose and 3.74 on 12 mg, against 2.12 on placebo, while body weight fell 20 to 24 percent. The drug is not approved by the FDA, patients who needed a knee replacement were excluded, and the trials were not designed to show whether it slows arthritis or reduces the need for surgery.
The International Pain and Spine Intervention Society's analysis of the 2027 Medicare Physician Fee Schedule final rule puts the impact for interventional pain at about a 2 percent decrease in allowed charges from relative value changes alone, on top of the 2.31 percent conversion factor cut for most physicians. A separate 20 percent cut applies when an office visit billed with modifier 25 is done the same day as a zero-day global procedure, paying only the highest-valued service in full. Two wins survived: CMS kept the exemption from multiple-procedure payment reductions for spinal cord stimulation and peripheral nerve stimulation procedures, and separate payment continues for qualifying non-opioid pain treatments through 2027. The traditional MIPS quality program's sunset was delayed to 2031.
- ChiropracticPhysical therapy
A JAMA Network Open study of 399,500 Medicaid adults with newly diagnosed acute low back pain found that the first treatment chosen predicted later opioid use disorder or overdose. Starting with higher-dose opioids (above 50 mg morphine equivalent) carried 146.6 percent higher risk, and prolonged lower-dose opioid use carried 105.2 percent higher risk, while starting with chiropractic care was linked to 32.8 percent lower risk and physical therapy to 31.1 percent lower risk. Fewer than half of patients received non-drug care first, despite guidelines recommending it. The study is observational, so it shows association, not proof that the first treatment caused the outcome.
CMS kept the January 1, 2027 start date for its mandatory Ambulatory Specialty Model in the November 4 final rule, even after an October 27 report from the Center for Healthcare Quality and Payment Reform warned the model could leave thousands of Medicare patients with low back pain and heart failure without specialty care. The model covers more than 5,500 specialists, including 626 pain management physicians and 395 interventional pain physicians, and the report notes total bonus payments are capped at 85 percent of total penalties, so the model is designed to cut pay for most participants. About one-third of the 235 areas in the model are fully rural, and on October 27 the American Hospital Association and other groups asked CMS to postpone the launch or drop the first year's downside risk.
Sources: Center for Healthcare Quality and Payment Reform, October 2026, https://chqpr.org/downloads/ExecSumm_Problems_with_ASM.pdf ; Becker's Hospital Review, October 27, 2026, https://www.beckershospitalreview.com/finance/cms-specialty-model-could-harm-rural-patients-report/
- California
The generic anti-inflammatory meloxicam has become the biggest source of anti-inflammatory drug spending in California workers' compensation, rising from 1.7 percent of the group's spending in 2020 to 30.8 percent in 2025, according to the California Workers' Compensation Institute. The average payment per prescription climbed from $9 in 2020 to $92 in 2025, even though the median payment was still under $14. The gap comes from four high-cost capsule products that made up only 12.6 percent of meloxicam prescriptions but 75.7 percent of the payments, a pattern the institute says warrants close attention from payers and prescribers.
- California
California's Division of Workers' Compensation has released its long-awaited proposed updates to the Medical Provider Network regulations, which govern the networks injured workers must use for care. A public hearing is set for Friday, December 11, 2026 at 1:00 p.m. Pacific in Oakland, and written comments are due the same day. Clinics in California networks should review the proposal now, since the rules shape which providers stay in networks and how network care is authorized.
Medicare will pay most physicians 2.31% less per relative value unit in 2027 under the final rule, a deeper cut than the 1.68% proposed in July. The conversion factor for physicians who do not qualify through an advanced alternative payment model falls from $33.40 to $32.63; for qualifying APM participants it falls 1.83%, from $33.57 to $32.95. The change takes effect January 1, 2027. Most of the decline comes from the expiration of a one-year 2.5% increase Congress provided for 2026.
The same-day visit penalty was softened from the proposal: CMS will pay 20% less for the lower-paid service when a separately identifiable office/outpatient evaluation-and-management visit (modifier -25) is billed the same day as a procedure with a 0-day global period, instead of the proposed 50%. Traditional MIPS reporting ends beginning with the CY 2031 performance period.
Sources: CMS press release, November 4, 2026; Medical Economics summary, November 4, 2026.
Source not linkedIssue postASC rates rise 2.3% for ASCs meeting quality-reporting requirements (3.2% market basket minus 0.9 productivity adjustment); hospital outpatient rates also rise 2.3%. CMS finalizes paying 340B-acquired drugs at ASP minus 28%, removes 637 services from the inpatient-only list in year two of the three-year phase-out, and expands site-neutral payment to imaging without contrast at excepted off-campus provider-based departments. CMS adds 618 procedures to the ASC-covered procedures list in the final rule; none of the 618 are spine or orthopedic procedures.
The high-volume pain-procedure cuts are also confirmed in the final rule: transforaminal lumbar/sacral epidural injections (CPT 64483) fall 3%, tied with facet radiofrequency ablation, facet joint injections, and carpal tunnel release as the biggest losses among the highest-spending ASC procedures — the second year in a row CMS has lowered ASC rates for those procedures.
Sources: CMS fact sheet, November 4, 2026; Becker's Spine Review final-rule analysis, November 5, 2026. Note: the 618 count and the pain-procedure cuts rest on Becker's analysis of the final rule, not on the CMS fact sheet, which does not state either figure. Dollar rates for individual codes were not re-verified from the final rule text and are not quoted here.
Source not linkedIssue postCMS's Ambulatory Specialty Model, a five-year mandatory model for selected regions, makes pain and spine specialists accountable for the cost and outcomes of chronic low-back-pain episodes, with a performance adjustment of -9% to +9% in the first payment years, rising to +/-12% by 2033.
Source not linkedIssue postA review published in the Journal of Occupational and Environmental Medicine, summarized October 27, 2026, found strong support for physical therapy and occupational therapy in reducing pain and restoring function across musculoskeletal conditions.
Source not linkedIssue postThe October 14, 2026 Federal Register notice sets a combined 7-OH + MGPI threshold (above 1 mg per gram for solids or per mL for liquids, or a mitragynine-to-7-OH/MGPI ratio below 100:1). A revised order is expected on or after November 13, 2026. Until it issues, 7-OH itself remains unscheduled. Natural leaf kratom is not the target of that order.
Pain Jobs — a job board for pain management professionals.
Source not linkedIssue post- VirginiaAcupuncture
Virginia's Board of Medicine has proposed fast-track amendments to its licensed-acupuncturist regulations that change every reference from the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) to its new name, the National Certification Board for Acupuncture and Herbal Medicine (NCBAHM). The change takes effect December 17, 2026, and public comments are due December 2. Tonight, November 12 at 8 p.m. Eastern, the American Society of Acupuncturists and NCBAHM hold a joint federal advocacy webinar on the push to reintroduce the Acupuncture for Our Seniors Act.
Sources: Virginia Register, November 2, 2026, http://register.dls.virginia.gov/details.aspx?id=12567 ; American Society of Acupuncturists, October 2026 newsletter, https://asacu.org/oct-2026-newsletter/
- MarylandMontana
Maryland's registered massage practitioners did not have to stop practicing on November 1 after all. Senate Bill 419 (Chapter 191), signed by the governor on April 28, 2026 and effective July 1, 2026, repealed the deadline that would have required every registered practitioner to hold a full license by November 1, so existing registrants can keep working under their registration while they convert to a license. A separate Maryland law that took effect October 1 requires massage advertisements to carry the therapist's full licensed name and license or registration number, and non-compliant physical signs must come down by May 1, 2027.
Sources: Maryland Senate Bill 419, Chapter 191, https://health.maryland.gov/massage/Documents/Senate_Bill_419_Massage_Therapy-Revisions.pdf ; https://www.massagedata.com/us/maryland/licensing
- FloridaTexasVirginia
The DEA has issued its first federal registrations to more than 900 state-licensed medical marijuana dispensaries in seven states, including Florida, Texas, and Virginia. The registrations are the first phase of the Attorney General's April 2026 order, which put qualifying state medical marijuana under Schedule III controls. Each dispensary had to pass a DEA pre-registration inspection, and the Attorney General said the regulated distribution "will help ensure broader access to chronic pain treatment." Dispensaries that applied in the April to June window but are still waiting must have a compliant supply chain in place by November 29, 2026. Recreational marijuana stays in Schedule I.